Cystic FibrosisPhase 1NCT06154447
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
A Phase 1 study testing VX-828, Itraconazole and Midazolam in people with Cystic Fibrosis, run by Vertex Pharmaceuticals Incorporated at 12 sites in United States.
Trial summary
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cystic Fibrosis
- What is being tested?
- VX-828, Itraconazole and Midazolam
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 165 participants
- Where
- 12 sitesUnited States
- Study dates
- 12 Dec 2023to 10 Jul 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Parts A-D:
- Participants between the ages of 18 and 55 years
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)
- A total body weight of more than (>) 50 kg
- Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening
- Cohort C2 only: Willing to provide a single DNA sample
Show all 12Show fewer
- Part E:
- Participants 18 years or older
- Confirmed diagnosis of CF as determined by the investigator
- A total body weight of more than or equal to (>=) 35 kg
- Participants must be heterozygous for F508del with a second CFTR allele carrying a minimal function mutation that is not responsive to ELX/TEZ/IVA therapy
- Participants must have a forced expiratory volume in 1 second (FEV1) of greater than or equal to (≥) 40% of predicted normal for age, sex, and height
Who cannot join
- Parts A-D:
- History of febrile illness or other acute illness within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
- Part E:
- An acute illness not related to CF (e.g., gastroenteritis) within 14 days before the first dose of study drug
- History of solid organ or hematological transplantation
Show all 9Show fewer
- History of clinically significant cirrhosis with or without portal hypertension
- Lung infection with organisms associated with a more rapid decline in pulmonary status
- Other protocol defined Inclusion/Exclusion criteria will apply.
Trial locations and contacts
12 sites in 1 country.
12 sites in 1 country
United States12 sites
Billings Clinic, Pediatric Pulmonary Dept.
Billings, Montana, 59101
Boston Children's Hospital
Boston, Massachusetts, 02115
Vermont Lung Center
Colchester, Vermont, 05446
Cook Children's Pulmonology
Fort Worth, Texas, 76104
New York Medical College
Hawthorne, New York, 10532
Joe DiMaggio Cycstic Fibrosis & Pulmonary Center
Hollywood, Florida, 33021
Kentucky Children's Hospital
Lexington, Kentucky, 40508
University of Minnesota -Pulmonology
Minneapolis, Minnesota, 55455
AdventHealth Medical Group Pulmonology at Orlando Ridgewood
Orlando, Florida, 32803
Altasciences Clinical Kansas
Overland Park, Kansas, 66212
University of Utah Hospital - Pulmonology
Salt Lake City, Utah, 84132
ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC
Toledo, Ohio, 43606
About this study
Official title: A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Read the detailed description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
- Conditions
- Cystic Fibrosis
- Being tested
- VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor
- Medical subject headings
- Cystic Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VX-828Drug
Suspension for Oral Administration
PlaceboDrug
Suspension for Oral Administration
ItraconazoleDrug
Solution for Oral Administration
MidazolamDrug
Syrup for Oral Administration
TezacaftorDrug
Also called TEZ, VX-661
Tablets for Oral Administration
VX-118Drug
Tablets for Oral Administration
PlaceboDrug
Suspension and Tablets for Oral Administration
DeutivacaftorDrug
Also called D-IVA, VX-561
Tablets for Oral Administration
VX-828Drug
Tablets for Oral Administration
| Study group | Role | What they receive |
|---|---|---|
| Part A: Single Ascending Dose (SAD) | Experimental | Participants will be randomized to receive a single dose of different dose levels of VX-828. Receives: Drug: VX-828 |
| Part A: Placebo | Placebo comparator | Participants will be randomized to receive placebo matched to VX-828. Receives: Drug: Placebo |
| Part B: Multiple Ascending Dose (MAD) | Experimental | Participants will be randomized to receive multiple doses of different dose levels of VX-828. The dose levels will be determined based on the data from Part A. Receives: Drug: VX-828 |
| Part B: Placebo | Placebo comparator | Participants will be randomized to receive placebo matched to VX-828. Receives: Drug: Placebo |
| Part C: Drug Drug Interaction | Experimental | Participants will receive a single dose of VX-828, followed by a washout period, Itraconazole administration, and concomitant administration of itraconazole and VX-828; or participants will receive Midazolam followed by VX-828/TEZ/D-IVA administration, and concomitant administration of VX-828/TEZ/D-IVA and Midazolam.
Part C will be an open-label optional cohort. Receives: Drug: VX-828; Drug: Itraconazole; Drug: Midazolam; Drug: Tezacaftor; Drug: Deutivacaftor |
| Part D: VX-828 in combination with TEZ/VX-118 ,TEZ/D-IVA or D-IVA | Experimental | Participants will be randomized to receive VX-828 in combination with TEZ/VX-118, TEZ/D-IVA, or D-IVA. Receives: Drug: VX-828; Drug: Tezacaftor; Drug: VX-118; Drug: Deutivacaftor |
| Part D: Placebo | Placebo comparator | Participants will be randomized to receive placebo matched to VX-828/TEZ/VX-118 or placebo matched to VX-828 in combination with TEZ/D-IVA or D-IVA Receives: Drug: Tezacaftor; Drug: Placebo; Drug: Deutivacaftor |
| Part E: VX-828 in Combination with D-IVA with or without TEZ in CF | Experimental | Participants with cystic fibrosis will receive VX-828 in combination with D-IVA with or without TEZ. Receives: Drug: Tezacaftor; Drug: Deutivacaftor; Drug: VX-828 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 67)
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)
Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)
Part E: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured: From Signing of Informed Consent Form (ICF) up to End of Study (Up to Day 111)
Part C: Maximum Observed Concentration (Cmax) of VX-828 in Plasma in the Absence and Presence of Itraconazole
Measured: From Day 1 up to Day 71
Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma in the Absence and Presence of Itraconazole
Measured: From Day 1 up to Day 71
Part C: Maximum Observed Concentration (Cmax) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA
Measured: From Day 1 up to Day 30
Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA
Measured: From Day 1 up to Day 30
Secondary outcomes (11)
Part A: Maximum Observed Concentration (Cmax) of VX-828 in Plasma
Measured: From Day 1 up to Day 67
Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma
Measured: From Day 1 up to Day 67
Part B: Maximum Observed Concentration (Cmax) of VX-828 at Day 28 in Plasma
Measured: From Day 1 up to Day 80
Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-828 at Day 28 in Plasma
Measured: From Day 1 up to Day 80
Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 82)
Part D: Maximum Observed Concentration (Cmax) of VX-828, TEZ and D-IVA and their Metabolites at Day 28 in Plasma
Measured: Day 28
Part D: Area Under the Concentration Versus Time Curve (AUC) of VX-828, TEZ and D-IVA and their Metabolites at Day 28 in Plasma
Measured: Day 28
Part E: Maximum Observed Concentration (Cmax) of VX-828, TEZ, and D-IVA and their Metabolites in Plasma
Measured: Day 1 and Day 28
Part E: Area Under the Concentration Versus Time Curve (AUC) of VX-828, TEZ, and D-IVA and their Metabolites in Plasma
Measured: Day 28
Part E: Pre-dose Plasma Concentration (Ctrough) of VX-828, TEZ, D-IVA and its Metabolites
Measured: Pre-dose at Day 4, Day 8, Day 15, Day 22, Day 35, Day 49, Day 63, Day 80
Part E: Absolute Change in Sweat Chloride
Measured: From Baseline and At Day 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2023
- Study start12 Dec 2023
- Primary completion10 Jul 2026
- Study completion10 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cystic FibrosisStudies of the same condition, open and under way.
- More trials run by Vertex Pharmaceuticals IncorporatedThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 165 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06154447
- Sponsor's protocol ID
- VX23-828-001
- Status last verified
- Aug 2026
- First submitted
- 23 Nov 2023
- Last updated
- 10 Aug 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis
- ClinicalTrials.gov ID
- NCT06154447
- Acronym / sponsor ID
- VX23-828-001
- Conditions
- Cystic Fibrosis
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 165 participants (actual)
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedIndustry (pharma, biotech, devices)
- Study start
- 12 Dec 2023 (actual)
- Primary completion
- 10 Jul 2026 (actual)
- Study completion
- 10 Jul 2026 (actual)
- First posted
- 4 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Detailed description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Part A: Single Ascending Dose (SAD) | Experimental | Drug: VX-828Participants will be randomized to receive a single dose of different dose levels of VX-828. |
| Part A: Placebo | Placebo comparator | Drug: PlaceboParticipants will be randomized to receive placebo matched to VX-828. |
| Part B: Multiple Ascending Dose (MAD) | Experimental | Drug: VX-828Participants will be randomized to receive multiple doses of different dose levels of VX-828. The dose levels will be determined based on the data from Part A. |
| Part B: Placebo | Placebo comparator | Drug: PlaceboParticipants will be randomized to receive placebo matched to VX-828. |
| Part C: Drug Drug Interaction | Experimental | Drug: VX-828, Drug: Itraconazole, Drug: Midazolam, Drug: Tezacaftor, Drug: DeutivacaftorParticipants will receive a single dose of VX-828, followed by a washout period, Itraconazole administration, and concomitant administration of itraconazole and VX-828; or participants will receive Midazolam followed by VX-828/TEZ/D-IVA administration, and concomitant administration of VX-828/TEZ/D-IVA and Midazolam. Part C will be an open-label optional cohort. |
| Part D: VX-828 in combination with TEZ/VX-118 ,TEZ/D-IVA or D-IVA | Experimental | Drug: VX-828, Drug: Tezacaftor, Drug: VX-118, Drug: DeutivacaftorParticipants will be randomized to receive VX-828 in combination with TEZ/VX-118, TEZ/D-IVA, or D-IVA. |
| Part D: Placebo | Placebo comparator | Drug: Tezacaftor, Drug: Placebo, Drug: DeutivacaftorParticipants will be randomized to receive placebo matched to VX-828/TEZ/VX-118 or placebo matched to VX-828 in combination with TEZ/D-IVA or D-IVA |
| Part E: VX-828 in Combination with D-IVA with or without TEZ in CF | Experimental | Drug: Tezacaftor, Drug: Deutivacaftor, Drug: VX-828Participants with cystic fibrosis will receive VX-828 in combination with D-IVA with or without TEZ. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Participants between the ages of 18 and 55 years
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)
- A total body weight of more than (>) 50 kg
- Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening
- Cohort C2 only: Willing to provide a single DNA sample
Key exclusion criteria (9 listed)
- History of febrile illness or other acute illness within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
- An acute illness not related to CF (e.g., gastroenteritis) within 14 days before the first dose of study drug
- History of solid organ or hematological transplantation
- History of clinically significant cirrhosis with or without portal hypertension
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VX-828Suspension for Oral Administration | Drug | Part A: Single Ascending Dose (SAD), Part B: Multiple Ascending Dose (MAD), Part C: Drug Drug Interaction, Part D: VX-828 in combination with TEZ/VX-118 ,TEZ/D-IVA or D-IVA |
| PlaceboSuspension for Oral Administration | Drug | Part A: Placebo, Part B: Placebo |
| ItraconazoleSolution for Oral Administration | Drug | Part C: Drug Drug Interaction |
| MidazolamSyrup for Oral Administration | Drug | Part C: Drug Drug Interaction |
| TezacaftorAlso: TEZ, VX-661Tablets for Oral Administration | Drug | Part C: Drug Drug Interaction, Part D: Placebo, Part D: VX-828 in combination with TEZ/VX-118 ,TEZ/D-IVA or D-IVA, Part E: VX-828 in Combination with D-IVA with or without TEZ in CF |
| VX-118Tablets for Oral Administration | Drug | Part D: VX-828 in combination with TEZ/VX-118 ,TEZ/D-IVA or D-IVA |
| PlaceboSuspension and Tablets for Oral Administration | Drug | Part D: Placebo |
| DeutivacaftorAlso: D-IVA, VX-561Tablets for Oral Administration | Drug | Part C: Drug Drug Interaction, Part D: Placebo, Part D: VX-828 in combination with TEZ/VX-118 ,TEZ/D-IVA or D-IVA, Part E: VX-828 in Combination with D-IVA with or without TEZ in CF |
| VX-828Tablets for Oral Administration | Drug | Part E: VX-828 in Combination with D-IVA with or without TEZ in CF |
Primary outcome
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 67)
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)
Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)
Part E: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Signing of Informed Consent Form (ICF) up to End of Study (Up to Day 111)
Part C: Maximum Observed Concentration (Cmax) of VX-828 in Plasma in the Absence and Presence of Itraconazole
Time frame: From Day 1 up to Day 71
Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma in the Absence and Presence of Itraconazole
Time frame: From Day 1 up to Day 71
Part C: Maximum Observed Concentration (Cmax) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA
Time frame: From Day 1 up to Day 30
Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA
Time frame: From Day 1 up to Day 30
11 secondary outcomes
Part A: Maximum Observed Concentration (Cmax) of VX-828 in Plasma
Time frame: From Day 1 up to Day 67
Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma
Time frame: From Day 1 up to Day 67
Part B: Maximum Observed Concentration (Cmax) of VX-828 at Day 28 in Plasma
Time frame: From Day 1 up to Day 80
Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-828 at Day 28 in Plasma
Time frame: From Day 1 up to Day 80
Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 82)
Part D: Maximum Observed Concentration (Cmax) of VX-828, TEZ and D-IVA and their Metabolites at Day 28 in Plasma
Time frame: Day 28
Part D: Area Under the Concentration Versus Time Curve (AUC) of VX-828, TEZ and D-IVA and their Metabolites at Day 28 in Plasma
Time frame: Day 28
Part E: Maximum Observed Concentration (Cmax) of VX-828, TEZ, and D-IVA and their Metabolites in Plasma
Time frame: Day 1 and Day 28
Part E: Area Under the Concentration Versus Time Curve (AUC) of VX-828, TEZ, and D-IVA and their Metabolites in Plasma
Time frame: Day 28
Part E: Pre-dose Plasma Concentration (Ctrough) of VX-828, TEZ, D-IVA and its Metabolites
Time frame: Pre-dose at Day 4, Day 8, Day 15, Day 22, Day 35, Day 49, Day 63, Day 80
Part E: Absolute Change in Sweat Chloride
Time frame: From Baseline and At Day 28
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Individual participant dataSharing planned: No. Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Related trials for Cystic Fibrosis
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
Active, not recruitingObservational study
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
Cystic Fibrosis, Bone Loss
RecruitingObservational study
Natural History of Bronchiectasis
Bronchiectasis, Cystic Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 2
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.
Cystic Fibrosis - Complete
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
12 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing VX-828, Itraconazole and Midazolam in people with Cystic Fibrosis, run by Vertex Pharmaceuticals Incorporated at 12 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 67)). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.